Article Sidebar
Views pdf: 40
EVALUATE RESPONSE RATE AND PROGRESSION-FREE SURVIVAL OF CONCURRENT CHEMORADIOTHERAPY REGIMEN ON PATIENTS WITH STAGE III NON-SMALL LUNG CANCER AT NGHE AN ONCOLOGY HOSPITAL
Main Article Content
Abstract
Objective: Evaluate response rate and progression-free survival of concurrent chemoradiotherapy regimen on patients with stage III non small cell lung cancer at Nghe An Oncology Hospital. Patients and Methods: The study describes, retrospects and prospects of 139 patients of stage III non small cell lung cancer received concurrent chemoradiotherapy regimen at Nghe An Oncology Hospital from March 2019 to March 2023. Results: The overall response rate of 78,4%, of which the complete response reached 1,4% and the partial response rate was 73,4 %, the disease stability rate was 10,1% and the disease progress rate was 15,1%. The disease control rate was 84,9%. There was a statistically significant association between the response rate with disease stage and completion of radiotion dose. The the median progression-free survival was 10,0 months. The progression-free survival is associated with response rate (HR=0,2, KTC 95%: 0,11 – 0,35, p=0,001), the disease stage IIIA (HR=0,27, KTC 95%:0,03-0,95, p = 0,044), the concurrent chemoradiotherapy Pemetrexed – Carboplatin regimen (HR = 0,41, KTC 95%: 0,19 – 0,89, p = 0,03). Conclusions: The concurrent chemoradiotherapy for stage III non small cell lung cancer at Nghe An Oncology Hospital had a complete response rate of 74,8 %; the median progression-free survival time was 10.0 months
Article Details
Keywords
: Non-small lung cancer, concurrent chemoradiotherapy.
References
2. Bradley, J.D., et al., Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol, 2020. 38(7): p. 706-714.
3. Spigel, D.R., et al., Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol, 2022. 40(12): p. 1301-1311.
4. Choi, H.S., et al., Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy. Radiat Oncol, 2017. 12(1): p. 122.
5. Senan, S., et al., PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 2016. 34(9): p. 953-62.
6. Liang, J., et al., Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol, 2017. 28(4): p. 777-783.
7. Belani, C.P., et al., Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol, 2005. 23(25): p. 5883-91.